Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers.

ABSTRACT: BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. Young adults and adults (Ya&A) were the most common patients treated with BV + AVD in clinical trials but have not been studied in non-trial settings. We conducted a real-life study in secondary and tertiary cancer centers to evaluate the PFS in 18-59 years aged patients who were scheduled to receive six BV + AVD for newly diagnosed advanced stage cHL. This is the largest cohort of Ya&A reported to date including 150 patients from four clinical institutions in Southern Italy, all of which employed structured supportive care programs for HL. Fifty patients (30%) had at least one ECHELON-1 ineligibility criterion, including comorbidities and/or adverse performance status. All 150 patients underwent BV + AVD with a med

SUBMITTER: Picardi M 

PROVIDER: S-EPMC12781149 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature